Hexima

Hexima Gross Margin

The Gross Margin of Hexima (HXL.AX) as of Nov 16, 2026 is 99.23 %. In the previous year, Gross Margin was 97.57 % — a change of 1.70% (higher).

Gross Margin

99.23 %

YoY

1.70%

Last updated:

Gross Margin of Hexima is 2023 99.23 % . Gross Margin of Hexima was 2022 97.57 % . It decreases by 1.70% higher compared to the previous year.

For Hexima, the gross margin of 99.2% is up versus 67.5% a few years ago.

The Hexima Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2016
74.83 AUD
Jan 1, 2017
70.27 AUD
Jan 1, 2018
70.27 AUD
Jan 1, 2019
67.53 AUD
Jan 1, 2020
-200.51 AUD
Jan 1, 2021
96.37 AUD
Jan 1, 2022
97.57 AUD
Jan 1, 2023
99.23 AUD
The Hexima Gross Margin history
YEARGross MarginYoY
99.23 %+1.70%
97.57 %+1.24%
96.37 %-148.07%
-200.51 %-396.92%
67.53 %-3.90%
70.27 %-0.01%
70.27 %-6.09%
74.83 %-8.64%
81.91 %+5.26%
77.82 %+9,539.03%
0.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hexima Stock analysis

What does Hexima do? Hexima Ltd. develops plant defensin peptides for human therapeutics, focusing on fungal nail infections. Its lead drug candidate, pezadeftide, is in phase II clinical trials for onychomycosis treatment. The company's Antifungal Plant Defensin Technology platform identifies plant peptides with antifungal properties against various fungal pathogens. Hexima targets pharmaceutical companies and healthcare providers seeking novel antifungal treatments. The firm generates revenue through research and development partnerships, licensing agreements, and future product sales. Phase II trial results will determine the next steps for pezadeftide, potentially leading to commercialization and sales. Hexima's technology platform supports multiple drug candidates beyond pezadeftide, aiming to address various fungal diseases. Hexima's primary market segment includes patients with onychomycosis and healthcare systems requiring effective antifungal therapies. The company collaborates with research institutions and pharmaceutical partners to advance its technology. Future revenue streams will depend on successful clinical outcomes and regulatory approvals for its drug candidates. Hexima is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hexima stock

Gross Margin of Hexima is 99.23 % in 2023.

Gross Margin of Hexima changed from 97.57 % to 99.23 %, representing a 1.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Hexima since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Hexima with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Hexima

All Key Metrics — Hexima